Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Immunology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Sarcoidosis Clinical Trials

A listing of Sarcoidosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (48) clinical trials

A research study is underway to see if a study medication works well and is safe when used as part of the treatment for pulmonary sarcoidosis.

Phase N/A

This study is designed to evaluate genetic mechanisms of lung disease by surveying polymorphic genes involved in respiratory function and examining gene expression in the lung cells of individuals with pulmonary disease (e.g., alpha 1-antitrypsin deficiency, asthma, chronic obstructive pulmonary disease, cystic fibrosis, sarcoidosis, history of infection, and genetic mutations ...

Phase N/A

Phase II Investigation of Antimycobacterial Therapy on Progressive Pulmonary Sarcoidosis

Primary Objective: To assess the efficacy and safety of oral CLEAR therapy in patients with confirmed progressive pulmonary sarcoidosis. Hypothesis: The CLEAR regimen will improve the absolute FVC percent predicted in chronic pulmonary sarcoidosis participants by augmenting T cell responses through the normalization of p56Lck expression and IL-2 production.

Phase

Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis

Glucocorticoids are the cornerstone of treatment of sarcoidosis and are used as the first-line agents in patients requiring immunosuppressive therapy.4 The optimal dose and duration of glucocorticoids is an unresolved issue. For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the ATS/ERS/WASOG is 20-40 mg per day.5 ...

Phase

A clinical trial sponsored by McMaster University for a research study for the treatment of Bronchopulmonary Dysplasia, Bronchiectasis, Asthma, Pulmonary sarcoidosis, Emphysema, alpha-1-Antitrypsin deficiency, Chronic Obstructive Lung Disease, Pulmonary Fibrosis

The primary objective of this study is to evaluate the ventilation defect percent (VDP), apparent diffusion coefficient (ADC) and/or the signal-to-noise ratio (SNR) obtained by analysis of hyperpolarized 129Xe MRI at one or more time-points (over time in the absence of therapeutic intervention or following clinically indicated therapy) in healthy ...

Phase N/A

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

The initial treatment of ocular sarcoidosis usually relies on a combination of topical glucocorticoids and oral glucocorticoids, both of which are associated with significant ocular and systemic toxicities. Steroid-sparing therapies are limited by variable and unpredictable efficacy, prolonged time until clinical response, medication intolerance, and difficulties obtaining payor approval. As ...

Phase N/A

Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis

In patients with sarcoidosis, cardiac death is a leading cause of mortality which may represent unrecognized cardiac involvement. Cardiovascular magnetic resonance (CMR) can detect cardiac involvement including minute amounts of myocardial damage. Therefore, the objective of this study was to determine the usefulness of CMR and compare it with standard ...

Phase N/A

ACTHAR Therapy for Central Nervous System Sarcoidosis

Central nervous system (CNS) involvement is one of the most severe manifestations of sarcoidosis. Sarcoidosis affecting the leptomeninges, spinal cord, or brain parenchyma portends a difficult course and frequently results in severe disability or death (1). Treatment of moderate and severe CNS sarcoidosis typically involves a combination of corticosteroids and ...

Phase

PET/MRI Imaging of Cardiac Sarcoidosis

PET/MRI scans will be performed with a whole-body PET/MR imaging system capable of simultaneous PET and MR imaging (SIGNA, GE Healthcare, Milwaukee, WI). Approximately 45-60 minutes after IV injection of 8 mCi of 18F-FSPG, PET emission scanning and MRI acquisition T1 weighted scanning will begin imaging both whole body and ...

Phase

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these ...

Phase N/A